Mucopolysaccharidosis type 4A (MPS IVA), also known as Morquio syndrome type A, is a rare inherited disorder belonging to the group of mucopolysaccharidoses caused by a deficiency of the enzyme N-acetylglucosamine-6-sulfatase. This disease is characterized by the accumulation of glycosaminoglycans in structural cells of the body, which leads to various systemic and skeletal disorders. MPS IVA has specific clinical manifestations such as skeletal dysplasia, cardiomegaly, problems with joint mobility and other systemic disorders. There is marked heterogeneity in the clinical picture among patients, which makes the diagnosis and treatment of this condition difficult.
History of the disease and interesting historical facts
The history of mucopolysaccharidoses dates back to the early 20th century, when glycosaminoglycan systems were first described. In 1966, the first MPS disease was identified, and Morquio syndrome was described in 1929 by a Scottish physician named Alan Morquio. At that time, the focus was on clinical manifestations, but adequate diagnostic and treatment methods did not exist until the 1970s. The discovery of the genetic basis of the diseases initiated the study of mutations that lead to enzyme deficiencies and accumulation of glycosaminoglycans. In recent decades, there has been significant progress in understanding the pathogenesis and clinical picture of the disease, which has contributed to earlier diagnosis and improved quality of life for patients.
Epidemiology
Prevalence statistics for mucopolysaccharidosis type 4A indicate that the disease occurs at a frequency of approximately 1 in 200,000 to 300,000 live births. This figure may vary depending on the geographic region and ethnicity of the population. Genetic studies indicate that mutations in the ARSB gene, located on chromosome 5, affect the severity of symptoms and the incidence of the disease. Most cases are diagnosed in childhood, but some cases may not be recognized until adolescence or young adulthood. The disease may remain asymptomatic for long periods of time, making it difficult to assess the true epidemiology of MPS IVA.
Genetic predisposition to this disease
Mucopolysaccharidosis type 4A is caused by mutations in the ARSB gene, which encodes the enzyme N-acetylglucosamine-6-sulfatase. The variety of mutations includes point mutations, insertions, and deletions, which result in impaired enzyme synthesis and, consequently, abnormal accumulation of glycosaminoglycans such as chondroitin-4-sulfate and keratan sulfate. The disease is inherited in an autosomal recessive manner, meaning that two mutant alleles are required for clinical signs to manifest. The risk of transmission of the disease is 25% for each subsequent child in families where both parents are carriers of the mutation. Studies show that new mutations can arise, increasing genetic diversity in the population.
Risk factors for the development of this disease
In most cases, mucopolysaccharidosis type 4A is caused by a genetic predisposition, but there are other risk factors, including:
- Hereditary predisposition - the presence of cases of MPS or other hereditary diseases in the family.
- Demographic factors - increased risk in certain ethnic groups and populations.
- Sexual predisposition - the disease occurs with equal frequency in both men and women, but some studies indicate more pronounced manifestations in men.
- Impact on the fetus during pregnancy - infectious diseases of the mother, which can affect the genetic load of the fetus.
Diagnosis of this disease
The main symptoms of mucopolysaccharidosis type 4A are:
- Skeletal dysplasia, including short limbs and short stature.
- Joint problems – limited mobility and pain syndromes.
- Ophthalmic disorders such as keratoconus.
- Cardiomegaly and other cardiovascular changes.
- Developmental delays and neurological complications.
Laboratory tests, such as measuring specific glycosaminoglycans in the urine and molecular genetic testing for mutations in the ARSB gene, are used to diagnose the disease. Radiological examinations, including X-rays and MRI, help identify changes in the skeleton and other organs. An important aspect is differential diagnostics, which allows excluding other diseases with similar clinical manifestations, such as other types of mucopolysaccharidoses and metabolic disorders.
Treatment
General treatment for mucopolysaccharidosis type 4A involves a comprehensive approach aimed at reducing symptoms and improving quality of life. There is currently no treatment regimen that can correct the genetic error. The main treatment strategies are:
- Pharmacological treatment, including the use of Enzyme Replacement Therapy (EZT) to correct the deficiency of the active enzyme.
- Surgical treatment to correct orthopedic disorders, including osteotomies, arthroplasty, and other procedures.
- Physiotherapy and rehabilitation to improve joint functionality and quality of life.
- Psychological support and social services for patients and their families.
List of medications used to treat this disease
The following drugs are currently used to treat mucopolysaccharidosis type 4A:
- Enzyme preparations - Viaparga (based on recombinant N-acetylglucosamine-6-sulfatase).
- Painkillers to control pain.
- Steroids to reduce inflammation.
- Pharmacological drugs to correct cardiovascular symptoms, such as beta blockers.
Disease monitoring
Monitoring of patients with mucopolysaccharidosis type 4A includes regular diagnostic examinations to assess disease progression and identify possible complications. The main control stages are:
- Regular surgical examinations to monitor conditions before and after treatment.
- Evaluation of functional capabilities and mobility of joints.
- Clinical and laboratory examinations to assess the function of the heart and other organs.
- Selection of optimal therapy, taking into account the individual characteristics of the patient.
The prognosis for patients varies depending on the severity and progression of the disease, but some patients can live into their 30s and 40s or longer if they receive proper medical care. Complications, including cardiovascular disease and joint problems, can significantly reduce quality of life.
Age-related features of the disease
The clinical presentation of mucopolysaccharidosis type 4A can vary significantly depending on the patient's age. In children, the first symptoms usually appear in early childhood, including delayed development, impaired motor skills, and other systemic manifestations. More serious orthopedic problems and the need for surgical intervention may develop in adolescence. In adult patients, the disease is often accompanied by chronic pain syndromes, deterioration of motor activity, and possible neurological disorders, which requires a more complex multidisciplinary approach to treatment.
Questions and Answers
- What causes mucopolysaccharidosis type 4A? The disease is caused by mutations in the ARSB gene, which leads to a deficiency of the enzyme N-acetylglucosamine-6-sulfatase.
- How to diagnose mucopolysaccharidosis type 4A? Diagnosis includes laboratory testing of urine for glycosaminoglycan levels and molecular genetic testing.
- Is there a treatment for mucopolysaccharidosis type 4A? Treatment is symptomatic, including enzyme replacement therapy and surgical interventions to correct structural changes.
- How does mucopolysaccharidosis type 4A affect people as they grow older? The disease can cause serious complications, affecting her physical condition and quality of life.
- What is the prognosis for a patient with mucopolysaccharidosis type 4A? The prognosis varies, but with adequate treatment some patients can live into their 30s or 40s or longer.
